A Phase Ib Study of Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Trial Profile

A Phase Ib Study of Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Alpelisib (Primary) ; Cetuximab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results (n=11) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 07 Apr 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
    • 11 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top